The inhibitor of HDAC, therefore, has been considered for clinical HCC treatment because people found that HDAC3 inhibitor suppressed HCV replication by increasing liver-expressed antimicrobial peptide 1(LEAP1) and decreasing apolipoprotein A1 (ApoA1). The gene discussed is HAMP; the disease is hepatocellular carcinoma.